Our Clinical Trials
Testing the safety and effectiveness of ourI-O drug candidates.
Coherus Oncology has multiple ongoing clinical trials across a range of cancer indications assessing our investigational immuno-oncology therapeutics.
| Study | Trial Overview |
|---|---|
|
Program:
Casdozokitug
Indications:
Hepatocellular Carcinoma (HCC)
Status:
Phase 2, ongoing
|
Trial Overview:
The randomized Phase 2 clinical trial (NCT06679985) is designed to evaluate the efficacy and safety of two pharmacologically active doses of casdozokitug in combination with toripalimab plus bevacizumab compared to toripalimab plus bevacizumab in 72 patients with first-line unresectable, locally advanced or metastatic HCC. For more information, please visit clinicaltrials.gov. |
|
Program:
Tagmokitug (CHS-114)
Indications:
Advanced Solid Tumors
Status:
Phase 1/1b, ongoing
|
Trial Overview:
The Phase 1/1b, open-label, first-in-human, dose-escalation and expansion clinical trial (NCT05635643) is designed to evaluate tagmokitug (formerly known as CHS-114) as a monotherapy in patients with advanced solid tumors and will be conducted in 3 parts: Arm 1a: Tagmokitug monotherapy dose-escalation portion of the study enrolled patients with advanced solid tumors. This study has been completed. Arm1b: Tagmokitug monotherapy expansion cohort(s) will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tagmokitug in head and neck squamous cell carcinoma patients. Arm 2: Tagmokitug + toripalimab combination dose-escalation portion of the study will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tagmokitug in combination with toripalimab in head and neck squamous cell carcinoma patients. Arm 3: Tagmokitug + toripalimab combination dose-expansion portion of the study will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tagmokitug in combination with toripalimab in patients with head and neck squamous cell carcinoma. For more information, please visit clinicaltrials.gov. |
|
Program:
Tagmokitug (CHS-114)
Indications:
Advanced Solid Tumors
Status:
Phase 1b, ongoing
|
Trial Overview:
The Phase 1b, multi-center, open-label, study (NCT06657144) is designed to evaluate tagmokitug (formerly known as CHS-114) in combination with toripalimab in patients with advanced solid tumors: Cohort A: Tagmokitug + toripalimab combination dose study will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tagmokitug in combination with toripalimab in patients with second line gastro-esophageal-junction (GEJ), or esophageal adenocarcinoma. Cohort B: Tagmokitug + toripalimab combination dose study will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tagmokitug in combination with toripalimab in patients with second line esophageal squamous cell carcinoma. Cohort C: Tagmokitug + toripalimab combination dose study will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tagmokitug in combination with toripalimab in patients with first line esophageal squamous cell carcinoma. Cohort D: Tagmokitug + toripalimab combination dose study will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tagmokitug in combination with toripalimab in patients with fourth line plus colorectal carcinoma. For more information, please visit clinicaltrials.gov. |
Investigator-Initiated Studies
Coherus Oncology supports independent, unsolicited research relating to disease areas of interest to Coherus Oncology or relating to Coherus Oncology products through its Investigator-Initiated Studies (“IIT”) and Pre-Clinical Material Transfer Agreement (MTA) programs in order to advance research and enhance disease understanding. To inquire about investigator-initiated studies, please send an email to: IST@coherus.com.
Educational Grants
To inquire about support for clinical, technical and scientific education programs, healthcare-related events or programs or charitable donations, please send an email to: CMEgrants@coherus.com.
We have multiple novel immuno-oncology programs currently in our development pipeline.
